Compare MRAM & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | ALEC |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 262.7M |
| IPO Year | 2016 | 2019 |
| Metric | MRAM | ALEC |
|---|---|---|
| Price | $9.41 | $2.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $4.83 |
| AVG Volume (30 Days) | 433.4K | ★ 753.5K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,417,000.00 | $21,045,000.00 |
| Revenue This Year | $10.87 | N/A |
| Revenue Next Year | $8.33 | $45.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $4.34 | $0.87 |
| 52 Week High | $17.24 | $3.40 |
| Indicator | MRAM | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 46.97 |
| Support Level | $8.42 | $1.82 |
| Resistance Level | $9.74 | $2.55 |
| Average True Range (ATR) | 0.58 | 0.17 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 28.25 | 24.26 |
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.